PEBP1 and triple-A syndrome: This study investigates the therapeutic potential of engineering biomimetic nanovesicles to deliver phosphatidylethanolamine‐binding protein 1 (PEBP1) mRNA for inhibiting ferroptosis in vascular smooth muscle cells (VSMCs) and preventing AAA progression.